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Abstract The effect of the opioid antagonists naloxone-
3-glucuronide and N-methylnaloxone on rat colon motility
after morphine stimulation was measured. The rat model
consisted of the isolated, vascularly perfused colon. The an-
tagonists (10−4 M, intraluminally) and morphine (10−4 M,
intra-arterially) were administered from 20 to 30 and from
10 to 50 min, respectively. Colon motility was deter-
mined by the luminal outflow. The antagonist concentra-
tions in the luminal and venous outflow were measured
by high-performance liquid chromatography. Naloxone-3-
glucuronide and N-methylnaloxone reversed the morphine-
induced reduction of the luminal outflow to baseline within
10 and 20 min, respectively. These antagonists were then
excreted in the luminal outflow and could not be found in
the venous samples. Naloxone, produced by hydrolysis or
demethylation, was not detectable. In conclusion, highly po-
lar naloxone derivatives peripherally antagonize the motility-
lowering effect of morphine in the perfused isolated rat colon,
are stable, and are not able to cross the colon-mucosal blood
barrier.
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Introduction
Opioid therapy is the mainstay of treatment for cancer-related
pain affecting approximately 9 million people worldwide an-
nually [1], and 55 to 95% of patients with advanced cancer
have severe pain [2]. Morphine (MO) is the drug of choice
for the management of moderate to severe chronic cancer
pain because of its effectiveness, tolerability, ease of use,
and low cost [3]. Unfortunately, constipation is one of the
most troublesome side effects of opioid therapy and often
adds to the distress of patients being treated for chronic pain
[4]. It is even a problem when opiates are administered on
a short-term basis for postoperative pain relief [5]. In ad-
dition to constipation, patients receiving opioids have other
aspects of opioid bowel dysfunction, including lower ab-
dominal discomfort, fecal impaction with overflow diarrhea
and incontinence, nausea, vomiting, and inadequate absorp-
tion of oral drugs [6]. Furthermore, it has been demonstrated
that functional deterioration in patients with advanced cancer
correlates closely with poor bowel function [7].
Whereas the analgesic action of opioids is mediated
through the central nervous system, constipation is a con-
sequence of their action on the gut wall, reducing intestinal
secretion and motility in both small and large bowel, with a
lengthening of gut transit time [8]. These adverse gastroin-
testinal opioid effects are produced through the activation of
central and peripheral µ-opioid receptors [9, 10]. The activa-
tion of peripheral receptors within the gastrointestinal tract
appears to be particularly important because the magnitude
of bowel dysfunction correlates more closely with opioid
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concentrations in the enteric nervous system than with con-
centrations in the central nervous system [11]. Similarly,
selective activation of gastrointestinal µ-opioid receptors by
poorly absorbed µ-opioid agonists, such as loperamide, re-
sults in profound inhibition of gastrointestinal transit [12].
The adverse effects of opioids on gastrointestinal function
can be reversed by antagonism of µ-receptors with cur-
rently available µ-opioid antagonists such as naloxone (NX)
and nalmefene. However, these antagonists are centrally
active, therefore they also antagonize analgesia and pre-
cipitate symptoms of opioid withdrawal in MO-dependent
subjects.
The development of µ-opioid receptor antagonists with
an action restricted to the periphery is therefore necessary
to prevent the effects of opioids on the gastrointestinal tract
without antagonizing the central effects, such as analgesia,
and producing opioid withdrawal symptoms.
In humans NX undergoes an extensive first-pass liver
effect with formation of the main metabolite naloxone-3-
glucuronide (NXG). In contrast to morphine-glucuronides
[13–15], the binding affinity and potency of NXG for opioid
receptors are not known. Whereas NX is easily absorbed,
we hypothesize that the highly polar NXG should not reach
the systemic circulation and, therefore, not reduce analge-
sia. A similar pharmacokinetic behavior is assumed by N-
methylnaloxone (MNX), like NXG, a peripherally acting
opioid receptor antagonist [16–20].
The aim of this study was to investigate in an isolated, arte-
rially perfused rat colon whether intraluminally (i.l.) admin-
istered NXG and MNX are able to normalize MO-delayed
colon transit without being absorbed into the systemic
circulation.
Methods
Preparation of the isolated perfused rat colon
The model of an isolated, vascularly perfused rat colon has
been described in detail elsewhere [21, 22]. Each colon
preparation was used just for one perfusion trial. Briefly,
adult Wistar rats of either sex weighing 250–300 g were used.
They were cared for in accordance with laboratory animal
care and use guidelines established by the Veterinary Ser-
vices of the Canton of Bern (animal assay permit no. 83/00).
Before operation, rats were fasted for 24 hr, with free access
to water. The animals were anesthesized with pentobarbital,
50 mg kg−1 body weight intraperitoneally, before midline
laparotomy. The hindgut and the upper small intestine were
freed up to the duodenum and separated after ligation of the
supplying vessels.
A silastic tube was inserted into the cecum. Similarly, the
distal descending colon was opened by a transverse inci-
sion, and the lumen was flushed with 20 ml of prewarmed
isotonic saline from the proximal end before a second silas-
tic tube was inserted into the distal descending colon. Sub-
sequently, the inferior mesenteric artery was divided dis-
tally of the left colic artery. Finally, the distal descending
colon was transected. At this point, the canulated colon (i.e.,
cecum, ascending, transversing, and descending colon) re-
ceives its arterial blood supply only from the superior mesen-
teric artery. The superior mesenteric artery and the supe-
rior mesenteric vein were next dissected and canulated with
polyethylene tubes (OD, 0.067 in.; Intramedic polyethylene
tubing, Becton Dickinson, Parsippany, NJ). Vascular perfu-
sion was started immediately after cannulation of the su-
perior mesenteric artery at a perfusion rate of 3 ml min−1
(Gibson Miniplus 3; Abimed, UK) to avoid any ischemia of
the colon. Finally, the canulated colon was freed from the
abdominal cavity by dividing the posterior attachments. Vas-
cular and luminal perfusion (LKB Microperpex Peristaltic
Pump Model. 2132; Pharmacia Biotech, Sweden) of the
colon was performed in a thermostatically controlled per-
fusion chamber (GFL Laborbedarf, Burgwedel, Germany)
[23]. Luminal perfusion was performed at a starting perfu-
sion rate of 0.75 ml min−1, resulting in an perfusion pressure
of 60 ± 5 mm Hg at the beginning of the experiments and in
the control animals. There was no apparent distention of the
colon at this perfusion rate. The luminal perfusion pressure
was continuously measured and kept constant by altering the
luminal perfusion rate if necessary. The luminal outflow rep-
resented the sum of motility actions, secretions, and resorp-
tions of the isolated perfused colon. Therefore we assumed
that the luminal outflow reflected colon motility. The vas-
cular and luminal perfusion fluid (modified Krebs-Ringer-
Henseleit solution) used was isosmolar with rat plasma
and had the following composition (mM): NaCl, 125; KCl,
4.3; MgCl2, 1; CaCl2, 2.5; NaHCO3, 25; NaH2PO4, 1; and
glucose, 5. The perfusion fluid was freshly prepared, fil-
tered through Schleicher & Schuell 597 filter paper (Dassel,
Germany) before use, had a pH of 7.4, and was bubbled with
O2 (95%) and CO2 (5%; Evaporator Type 2362; Liebich,
Bielefeld, Germany). The temperature was maintained at
37◦ ± 0.3◦C. Viability of each colon was tested at the end
of the experiment by its ability to contract after a mechanical
stimulus.
Colon motility and outflow measurements
The agonist solution consisted of 10−4 M MO (morphine hy-
drochloride trihydrate Ph. Eur.; Merck, provided by Grogg,
Bern, Switzerland) dissolved in perfusion fluid. This con-
centration resulted from a preceding dose-finding study with
10−6, 10−5, and 10−4 M MO. The solution was applied
intra-arterially (i.a.) from 10 to 50 min after T0 ( = time
point of steady state). The equimolar antagonist solutions
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were prepared by dissolving 10−4 M NXG (naloxone-3-β-d-
glucuronide hydrate; Lipomed, Arlesheim, Switzerland) or
10−4 M MNX (naloxone methiodide; Sigma-Aldrich, Buchs,
Switzerland) in perfusion fluid. Perfusion fluid was used as
placebo solution. NXG (n = 9), MNX (n = 6), and placebo
(n = 3) solutions were applied intraluminally (i.l.) from 20 to
30 min after T0. Luminal and venous outflow samples were
collected during 5-min intervals starting 5 min before (base-
line) and 5, 15, 25, 35, and 45 min after the administration
of MO. The luminal and venous outflows were determined
by weighing. There was no significant difference between
arterial inflow and venous outflow, indicating the absence of
significant resorption (data not shown).
Determination of NX, NXG, and MNX in the luminal
and venous outflow by HPLC
An ASPEC XL robotic system (Gilson, Villiers Le Bel,
France) was used for extraction of the biological samples. To
1 ml luminal outflow, diluted 1:10 with perfusion fluid and fil-
trated, or 1 ml venous outflow, undiluted and filtrated, 100 µl
internal standard solution (1.5 mg ethylmorphine hydrochlo-
ride Ph. Eur. [Merck], dissolved in 100 ml bidistillated water)
and 3.0 ml 0.5 M carbonate buffer, pH 9.3, were added. Af-
ter vortexing, the mixture was applied to solid phase extrac-
tion (SPE) columns (Chromabond C-18 ec, 3 ml, 500 mg;
Macherey-Nagel, Oensingen, Switzerland), preconditioned
with two aliquots of 2.5 ml methanol, 40% acetonitrile in
0.01 M phosphate buffer pH 2.1 (v/v), and bidistillated wa-
ter, respectively. After washing with six aliquots of 2.5 ml
0.005 M carbonate buffer, pH 9.3, 0.5 ml water, and 0.5 ml
40% acetonitrile in 0.01 M phosphate buffer, pH 2.1 (v/v),
elution was performed with three aliquots of 1.0 ml 70%
acetonitrile in 0.01 M phosphate buffer, pH 2.1 (v/v). The
eluate was then concentrated at 45◦C under N2 to dryness,
redissolved in 120 µl HPLC mobile phase A (see below),
sonicated, and filtrated. Eight microliters of the SPE extracts
was then used for HPLC analysis. An Agilent 1100 Series
Capillary HPLC System (Agilent Technologies, Waldbronn,
Germany) was used. The extracts were separated at 45◦C
on a Zorbax XDB C-8 3-µm column (Agilent Technologies;
150 × 0.5 mm i.d.) using a multistep gradient (mobile phase
A, bidistilled water + 0.05% trifluoroacetic acid [v/v]; B,
acetonitrile + 0.05% trifluoroacetic acid; 3% B [0–6 min],
3%–12% B [6–14 min], 12%–20% B [14–20 min], 20%–
100% B [20–21 min], 100% B [21–30 min], 100%–3% B
[30–35 min], 3% B [35–45 min]; flow rate of 15 µl min−1).
Quantitation of NX, NXG, and MNX was performed at 205
nm (diode array detector) based on peak areas and using the
internal standard method. Validation data were as follows:
SPE extraction efficiency, 66–91%; calibration graph, linear
in the range of 50–9000 ng ml−1, r2 > 0.993; intra- and
interassay precision, ± 1.2%–7.0% RSD; intra- and inter-
assay accuracy, −1.8% to −1.3%; limits of quantitation and
detection, 20 and 10 ng ml−1, respectively (signal-to-noise
ratio, 5:1).
Statistics
Statistical analysis was performed with SPSS version 11
(Mac) using the Mann-Whitney test (nonparametric). Sig-
nificance was assessed at the P < 0.05 level (two-
tailed).
Results
Effect of NXG on the isolated rat colon
motility inhibited by MO
Figure 1 shows that the luminal outflow of the isolated,
perfused rat colon was reduced by 10−4 M i.a. MO, from
7.74 ± 0.41 to 5.10 ± 0.32 g (mean ± SEM; n = 9) within
10 min. Therefore, 20 min after T0 the colon motility was de-
creased to 66.8% ± 2.2% of the baseline value. With a lumi-
nal outflow of 7.62 ± 0.48 g (P = 0.009), this colon motility-
inhibiting effect was, from 20 to 30 min, almost reversed to
baseline by 10−4 M i.l. NXG. The MO effect reappeared
10 min after stopping the NXG administration. When using
placebo (perfusion fluid; n = 3) the colon motility-inhibiting
effect by MO was not much influenced between 20 and
40 min. After 50 min the outflow was similar for NXG and
placebo.
Effect of MNX on the isolated rat colon motility
inhibition by MO
The luminal outflow was reduced by 10−4 M i.a. MO from
6.73 ± 0.31 to 4.06 ± 0.24 g (mean ± SEM; n = 6)
within 10 min (Fig. 2), corresponding to 60.4% ± 2.7%
of the baseline motility. Fourty minutes after T0, 10−4 M
i.l. MNX increased the luminal outflow to 7.53 ± 0.28 g
(P = 0.02), corresponding to 97.7% ± 4.6% of the baseline
value.
NXG and MNX levels in the luminal and
venous outflow of the isolated rat colon
In the luminal outflow samples collected after i.l. NXG, the
NXG concentrations measured by a fully validated HPLC
method ranged from 0 (baseline) to 88.38 µg ml−1. In the
venous outflow no NXG and NX could be detected. After
i.l. MNX, the luminal MNX concentrations varied between
0 (baseline) and 33.69 µg ml−1. Again, no MNX was de-
tectable in the venous outflow.
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Fig. 1 Luminal outflow of the
isolated, perfused rat colon after
i.a. administration of 10−4 M
MO from 10 to 50 min, 10−4 M
i.l. NXG from 20 to 30 min
(•; n = 9), and 10−4 M i.l.
placebo (perfusion fluid) from
20 to 30 min (; n = 3). The
graphs show the reversal effect
of the opioid antagonist NXG on
the MO-stimulated colon
motility inhibition vs. placebo.
∗Significant at P < 0.05 vs.
placebo
Discussion
The ex vivo model of the isolated, vascularly perfused rat
colon used in this study proved to be suitable and robust
for measuring agonistic and antagonistic effects of opioids
on the colonic motility. In a dose-finding study, micromolar
concentrations of MO resulted in the best organ response. In
addition, these rather high concentrations are in accordance
with those used in previous opioid experiments on isolated
rat colons [24, 25] as well as guinea pig ileal circular muscle
[26].
To the best of our knowledge, the present data show,
for the first time, that the opioid glucuronide NXG exerts
a peripheral effect on colon motility similar to that of the
quarternary opioid MNX. In contrast to placebo, NXG and
MNX administered i.l. significantly reversed the effects of
i.a. MO on colonic motility. Neither NXG or MNX given
i.l. nor NX could be detected in the venous outflow of the
organ preparation. These findings suggest that the highly
polar opioid antagonists are not able to pass the colonic
mucosal blood barrier. Furthermore, the absence of NX in
the venous outflow indicates that NXG and MNX are lu-
minally not hydrolyzed and demethylated, respectively, by
Fig. 2 Luminal outflow of the
isolated, perfused rat colon after
i.a. administration of 10−4 M
MO from 10 to 50 min and of
10−4 M i.l. MNX from 20 to
30 min (n = 6). The graph
shows the reversal effect of the
opioid antagonist MNX on the
MO-stimulated colon motility
inhibition. ∗Significant at P <
0.05 vs. placebo
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enzymes or bacteria to the easily absorbable NX. The latter
phenomenon has been described for chronic pain patients
treated with MO, where NX reduced constipation but caused
opioid withdrawal symptoms [27]. This indicates a central
effect of NX despite the well-known first-pass glucuronida-
tion of NX in the liver. Similar observations were made in
advanced cancer patients, where NX at doses >20% of the
24-hr dose of MO had a marked laxative effect but also pro-
duced opioid withdrawal signs in some of the patients [28].
Further studies were postulated evaluating the ideal dose of
oral NX which exerts the peripheral laxative effect without
producing withdrawal symptoms.
In rats where oral NX reversed the constipating effects
of oral MO, no influence on nociception was observed [29].
It was concluded that an extensive metabolization of NX is
responsible for the lack of central activity.
Our results support the findings that in MO-dependent
rats, peroral NXG induced diarrhea without signs of MO-
induced withdrawal, as observed with NX [5]. It was demon-
strated in rats that subcutaneously administered NX, in con-
trast to quartenary opioid antagonists, decreased peripheral
as well as central effects of MO-dependent rats [30].
Human studies performed in healthy volunteers and in
human subjects on a methadone program showed that oral N-
methylnaltrexone shortened the orocecal transit time without
producing withdrawal symptoms [12, 31–33].
Quarternary opioid antagonists are suggested, according
to results of subcutaneous, oral, and intravenous adminis-
tration, to be unable to cross the blood-brain barrier and
thus to explain the lack of opioid withdrawal symptoms un-
der the respective treatment. Our study with MNX and NXG
in the rat organ preparation indicates that both substances
are unable to cross the colon-mucosal blood barrier.
However, further in vitro and in vivo studies are needed,
for example, to further characterize the receptor binding
affinity of NXG and to clinically elucidate the present study
findings in healthy volunteers and patients.
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